Literature DB >> 14999768

A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease?

Marco Tomasetti1, Nina Gellert, Antonio Procopio, Jiri Neuzil.   

Abstract

Malignant mesothelioma is a fatal type of neoplasia of the pleura and the peritoneum with currently no known cure. Therefore, discovery of an efficient antimesothelioma drug with low deleterious side effects is desirable. Here, we studied in vivo the effect of alpha-tocopheryl succinate, a semisynthetic vitamin E analogue with proapoptotic and anticancer activity and selectivity for malignant cells, on experimental peritoneal mesothelioma using immunocompromised mice. Compared to untreated animals, the agent increased their survival >3-fold. Our finding warrants further testing of vitamin E analogues as potential antimesothelioma drugs. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999768     DOI: 10.1002/ijc.20062

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function.

Authors:  Marco Tomasetti; Linda Nocchi; Sara Staffolani; Nicola Manzella; Monica Amati; Jacob Goodwin; Katarina Kluckova; Maria Nguyen; Elisabetta Strafella; Martina Bajzikova; Martin Peterka; Sandra Lettlova; Jaroslav Truksa; Wan Lee; Lan-Feng Dong; Lory Santarelli; Jiri Neuzil
Journal:  Antioxid Redox Signal       Date:  2014-04-23       Impact factor: 8.401

Review 2.  Inhibitors of succinate: quinone reductase/Complex II regulate production of mitochondrial reactive oxygen species and protect normal cells from ischemic damage but induce specific cancer cell death.

Authors:  Stephen J Ralph; Rafael Moreno-Sánchez; Jiri Neuzil; Sara Rodríguez-Enríquez
Journal:  Pharm Res       Date:  2011-08-24       Impact factor: 4.200

3.  Mitochondrially targeted α-tocopheryl succinate is antiangiogenic: potential benefit against tumor angiogenesis but caution against wound healing.

Authors:  Jakub Rohlena; Lan-Feng Dong; Katarina Kluckova; Renata Zobalova; Jacob Goodwin; David Tilly; Jan Stursa; Alena Pecinova; Anatoly Philimonenko; Pavel Hozak; Jaideep Banerjee; Miroslav Ledvina; Chandan K Sen; Josef Houstek; Mark J Coster; Jiri Neuzil
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

4.  Mitochondrial targeting of α-tocopheryl succinate enhances its anti-mesothelioma efficacy.

Authors:  Jaromira Kovarova; Martina Bajzikova; Magdalena Vondrusova; Jan Stursa; Jacob Goodwin; Maria Nguyen; Renata Zobalova; Elham Alizadeh Pesdar; Jaroslav Truksa; Marco Tomasetti; Lan-Feng Dong; Jiri Neuzil
Journal:  Redox Rep       Date:  2013-11-12       Impact factor: 4.412

5.  Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents.

Authors:  Elham Alizadeh Pasdar; Michael Smits; Michael Stapelberg; Martina Bajzikova; Marina Stantic; Jacob Goodwin; Bing Yan; Jan Stursa; Jaromira Kovarova; Karishma Sachaphibulkij; Ayenachew Bezawork-Geleta; Margaryta Sobol; Anatoly Filimonenko; Marco Tomasetti; Renata Zobalova; Pavel Hozak; Lan-Feng Dong; Jiri Neuzil
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

6.  Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells.

Authors:  M Tomasetti; M R Rippo; R Alleva; S Moretti; L Andera; J Neuzil; A Procopio
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.